KR0176015B1 - Periodontal disease prevention and treatment composition - Google Patents
Periodontal disease prevention and treatment composition Download PDFInfo
- Publication number
- KR0176015B1 KR0176015B1 KR1019960008393A KR19960008393A KR0176015B1 KR 0176015 B1 KR0176015 B1 KR 0176015B1 KR 1019960008393 A KR1019960008393 A KR 1019960008393A KR 19960008393 A KR19960008393 A KR 19960008393A KR 0176015 B1 KR0176015 B1 KR 0176015B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- periodontal disease
- jujube
- composition
- thick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 53
- 230000006806 disease prevention Effects 0.000 title claims abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 136
- 241001247821 Ziziphus Species 0.000 claims abstract description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 11
- 239000000606 toothpaste Substances 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- 229940034610 toothpaste Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 235000002566 Capsicum Nutrition 0.000 claims description 3
- 239000006002 Pepper Substances 0.000 claims description 3
- 241000722363 Piper Species 0.000 claims description 3
- 235000016761 Piper aduncum Nutrition 0.000 claims description 3
- 235000017804 Piper guineense Nutrition 0.000 claims description 3
- 235000008184 Piper nigrum Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- 238000013329 compounding Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 44
- 241000219122 Cucurbita Species 0.000 description 14
- 235000009852 Cucurbita pepo Nutrition 0.000 description 14
- 230000003239 periodontal effect Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000000845 anti-microbial effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 244000126002 Ziziphus vulgaris Species 0.000 description 10
- 239000009429 Ginkgo biloba extract Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 8
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 7
- 229940068052 ginkgo biloba extract Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 231100000676 disease causative agent Toxicity 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940116257 pepper extract Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- 235000014443 Pyrus communis Nutrition 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 3
- 235000019477 peppermint oil Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 240000007311 Commiphora myrrha Species 0.000 description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000335876 Porphyromonas gingivalis W50 Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- XETHJOZXBVWLLM-HUKCQOFTSA-N (5ar,10as)-2-[(1s,5s,6r)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-1,3,8,10a-tetrahydroxy-5a-(3-methylbut-2-enyl)-[1]benzofuro[3,2-b]chromen-11-one Chemical compound O=C([C@@H]1[C@H](CC(C)=C[C@@H]1C1=C(O)C=C2O[C@]3([C@](C(=O)C2=C1O)(O)OC=1C3=CC=C(O)C=1)CC=C(C)C)C=1C(=CC(O)=CC=1)O)C1=CC=C(O)C=C1O XETHJOZXBVWLLM-HUKCQOFTSA-N 0.000 description 1
- QUOANUOITQPOFA-UHFFFAOYSA-M 2-(2,5-diphenyltetrazol-1-ium-1-yl)-4-methyl-1,3-thiazole;bromide Chemical compound [Br-].CC1=CSC([N+]=2N(N=NC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 QUOANUOITQPOFA-UHFFFAOYSA-M 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000314459 Prevotella intermedia ATCC 25611 = DSM 20706 Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- SUOXGDJCEWTZIZ-UHFFFAOYSA-N Sanggenon C Natural products OC1=C2C(=O)C3(CC=C(C)C)OC4=CC(O)=CC=C4C3(O)OC2=CC(O)=C1C1C=C(C)CC(C=2C(=CC(O)=CC=2)O)C1C(=O)C1=CC=C(O)C=C1O SUOXGDJCEWTZIZ-UHFFFAOYSA-N 0.000 description 1
- NUKIHHJPIBKEPM-UHFFFAOYSA-N Sanggenon D Natural products CC(=CCC12Oc3cc(O)ccc3C1(O)Oc4cc(O)c(C5C=C(C)CC(C5C(=O)c6cc(O)cc(O)c6)c7ccc(O)cc7O)c(O)c4C2=O)C NUKIHHJPIBKEPM-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940018158 hydroxypropylcellulose 5 mg Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 235000012420 sanguinaria Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 대추 추출물과 후박 추출물을 유효성분으로 함유하는 치주질환 예방 및 치료제 조성물에 관한 것이다. 본 발명에 따르는 대추 추출물과 후박 추출물 함유 조성물은 특정의 배합비, 즉 중량기준으로 1 : 6내지 1 : 12, 특히는 1 : 8내지 1 : 10의 배합비에서 각각의 성분을 단독으로 사용한 경우에 비해 월등히 우수한 상승적 효과를 나타낼 뿐 아니라, 기존의 치주질환 예방 및 치료제에 비해서도 월등히 우수한 치주질환 치료효과를 나타낸다.The present invention relates to a periodontal disease prevention and treatment composition comprising the jujube extract and the thick extract as an active ingredient. The jujube extract and the thick extract extract-containing composition according to the present invention have a specific compounding ratio, i.e., a compounding ratio of 1: 6 to 1: 12, and particularly 1: 8 to 1: 10, Not only does it show an excellent synergistic effect, it also shows an excellent treatment of periodontal disease compared to existing periodontal disease prevention and treatment.
Description
본 발명은 치주질환 예방 및 치료제 조성물에 관한 것이다.The present invention relates to a composition for preventing and treating periodontal disease.
치과 질환은 치아우식증(충치)과 치주질환으로 크게 대별된다. 이중에서 치주질환은 구강질환중 성인에게서 가장 빈발하는 감염성 질환으로, 치은출혈과 종창, 치주낭의 형성 및 치조골의 파괴 등으로 인한 치아의 상실을 가져오는 것을 말한다. 치주질환의 발생기전을 살펴보면, 치태가 치주낭내에 기계적으로 축적되면 주변에 존재하는 세균들의 서식처가 되며 이러한 서식은 점차 호기성, 통기성 그람 양성세균에서 혐기성 그람 음성세균으로 점차 이행되고, 치주낭의 심부로 증식되게 된다. 이때 증식된 혐기성 그람음성세균의 독소 및 모든 산물은 직접 조직을 파괴하거나 면역계를 자극하여 자극된 면역계로부터 여러가지 작용에 의하여 치주조직 파괴와 더불어 염증을 유발하게 된다.Dental diseases are roughly divided into dental caries (cavities) and periodontal disease. Among these, periodontal disease is the most common infectious disease in adults among oral diseases, and it refers to loss of teeth due to gingival hemorrhage, swelling, periodontal sac formation, and destruction of alveolar bone. The mechanism of periodontal disease is that when the plaque is mechanically accumulated in the periodontal sac, it becomes a habitat for the bacteria present in the surrounding area, which gradually transitions from aerobic and breathable Gram-positive bacteria to anaerobic Gram-negative bacteria and proliferates deep into the periodontal sac. Will be. At this time, the toxins and all products of the proliferated anaerobic Gram-negative bacteria directly destroy tissues or stimulate the immune system and cause inflammation along with periodontal tissue destruction by various actions from the stimulated immune system.
이러한 치주질환을 야기하는 원인균은 치아우식증의 경우와는 달리 구강내 미생물중 그람음성균인 포르피모나스 깅기발리스(Porphymonas gingivalis), 프레보텔라 인터메디아(Prevotella intermedia), 악티노바실러스 악티노미세템코미탄스(Actinobacillus actinomycetemcomitans) 등이다.Unlike the case of dental caries, the causative agent causing such periodontal disease is Gram-negative bacteria of the oral microorganisms, Porphymonas gingivalis, Prevotella intermedia, Actinobacillus actinomycetem. Comitans (Actinobacillus actinomycetemcomitans).
또한 이러한 치주질환이 주로 성인에게서 나타나는 이유는 치주조직이 나이가 들어감에 따라 점점 약화되기 때문이다.Also, the reason why these periodontal diseases appear mainly in adults is that the periodontal tissues are gradually weakened with age.
따라서 치주질환을 예방 또는 치료하기 위하여는 상기 언급한 바와 같은 치주질환의 원인을 모두 해소시킬수 있는 , 즉 1) 약화되거나 파괴된 치주조직을 원상으로 회복시키고, 2) 치주질환 원인균의 독성산물인 염증을 제거하고, 3) 치주질환 원인균을 억제할 수 있는 방법을 이용하는 것이 가장 바람직하다.Therefore, in order to prevent or treat periodontal disease, all the causes of periodontal disease as described above can be resolved, that is, 1) restoring weakened or destroyed periodontal tissues to its original state, and 2) inflammation which is a toxic product of periodontal disease-causing bacteria. It is most preferable to use a method that can remove 3, and inhibit the causative agent of periodontal disease.
치주질환 예방 및 치료제에 대한 연구는 1920 년대부터 진행되어 왔으며, 특히 구미 각국에서는 항생제 및 화학요법제(예를 들면, 클로르헥시딘, 세틸피리디늄)에 의한 항균효과를 이용하여 치태를 제거하는데 주력하여 왔다.Research on the prevention and treatment of periodontal disease has been in progress since the 1920s, especially in Western countries, focusing on eliminating plaque using antimicrobial effects of antibiotics and chemotherapeutic agents (eg, chlorhexidine, cetylpyridinium). .
그러나 이러한 항생제 및 화학요법제들은 구강점막 궤양, 박리성 치은염 유발, 착색 등의 부작용이 있어 문제가 되고 있다.However, these antibiotics and chemotherapeutic agents are problematic due to side effects such as oral mucosal ulceration, exfoliative gingivitis, and pigmentation.
또한, 항생제나 화학요법제 이외에 치태간질을 분해하는 효소제제, 세균이 치아표면에 흡작되는 것을 방지하는 불소제제 등도 치주질환의 치료를 위해 사용되었으나 효소들은 부작용과 적용방법에 있어 문제점이 있고, 불소제제는 항균효과가 미약해서 보편적 사용이 제한되고 있다.In addition to antibiotics and chemotherapeutic agents, enzymes that degrade plaque epilepsy and fluorides that prevent bacteria from absorbing on the tooth surface have been used for the treatment of periodontal disease, but enzymes have side effects and application methods. The formulations have a weak antimicrobial effect, which limits their universal use.
이러한 항생제를 비롯한 합성의약품의 사용에 따른 단점을 해결하기 위하여 생약추출물을 이용하여 치주질환을 치료하는 약물을 개발하고자 하는 연구가 진행되었다. 그 결과, 몰약(Myrrha)은 치은염, 아구창에 효과가 있고, 상백피 추출물 성분인 상게논(Sanggenon) C는 스트렙토코커스 뮤탄스(Streptococcus mutans)의 대사를 저해하여 치태형성의 제1단계인 균부착을 방해하는 것으로 밝혀졌으나, 몰약은 항균효과가 미약하고, 상백피 추출물은 치은섬유아세포의 증식을 상당한 수준으로 억제하는 단점이 있다.In order to solve the disadvantages of the use of synthetic drugs, including antibiotics, research has been conducted to develop drugs to treat periodontal disease using herbal extracts. As a result, Myrrha is effective for gingivitis and thrush, and Sanggenon C, an extract of the lettuce extract, inhibits the metabolism of Streptococcus mutans, resulting in the first stage of plaque formation. Although it has been found to interfere, myrrh has a weak antimicrobial effect, and the extract of Morus vulgaris has the disadvantage of inhibiting the proliferation of gingival fibroblasts to a significant level.
그밖에도 상귀나리아 추출물(Sanguinaria extract)은 실험실 실험에서는 강력한 치태억제 및 항균효과를 나타내는 것으로 밝혀졌지만, 임상실험 결과로는 소망하는 효과를 얻을 수 없다는 단점이 있다.In addition, Sanguinaria extract has been shown to exhibit potent plaque suppression and antimicrobial effects in laboratory experiments, but clinical trial results do not provide the desired effect.
또한, 옥수수[지 메이(Zea mays L.)]의 추출물도 현재 인사돌정(동국제약), 덴톨정(럭키) 등의 상표로 시판되고 있으며, 치주조직내의 염증을 억제할 목적으로 사용되어 왔다.In addition, the extract of corn (Zea mays L.) is also commercially available under the trademarks such as Insadol (Dongkuk) and Dentol (Lucky), and has been used for the purpose of suppressing inflammation in the periodontal tissue.
그러나 이러한 종래의 생약을 이용한 치주질환 치료제들은 부작용이 없다는 장점은 있으나, 치주질환으로 손상된 치주조직세포에 대한 재생력이 없거나, 치주질환을 야기하는 원인균에 대한 항균작용이 없다는 단점이 있어 바람직하지 못하였다.However, the treatment of periodontal disease using the conventional herbal medicine has the advantage that there are no side effects, but it is not preferable because there is no regeneration of the periodontal tissue cells damaged by the periodontal disease, or there is no antibacterial action against the causative bacteria causing the periodontal disease. .
이에 본 발명자들은 상기의 생약을 이용한 치주질환 치료제들의 단점을 극복한 우수한 치주질환 치료제를 개발하고자 여러가지 생약을 이용하여 집중적인 연구를 수행하였으며, 그 결과로 후박 추출물이 기존의 항생제와 같은 부작용이 없으면서 우수한 항염작용과 함께 치주질환의 원인균에 대한 강력한 항균작용을 나타내는 것을 밝혀내었으며(참조 : 한국특허공개 제94-6594호), 은행잎 추출물이 치주 조직에 대한 재생효과를 나타내는 것도 확인하였다(참조 : 한국특허출원 제94-13606호). 본 발명자들은 또한 후박 추출물과 은행잎 추출물을 배합한 조성물이 치주질환 전반에 우수한 효과가 있음을 확인하여 이들을 대상으로 하는 치주질환 치료제 조성물에 관하여 특허를 출원한 바 있다(참조 : 한국특허출운 제94-14117호) 그후 계속적인 연구의 결과로, 대추 추출물이 또한 치주조직의 재생에 우수한 효과를 나타냄을 확인하여 대추 추출물을 이용한 치주질환 치료제에 관하여도 특허출원을 하였다(참조 : 한국특허출원 제95-14541호).Therefore, the present inventors conducted intensive research using various herbal medicines to develop excellent periodontal disease treatment agents that overcome the disadvantages of the above-mentioned herbal medicines for periodontal disease treatment. In addition to excellent anti-inflammatory activity, it has been shown to exhibit strong antimicrobial activity against the causative agent of periodontal disease (Korean Patent Publication No. 94-6594), and it was also confirmed that ginkgo biloba extract showed a regenerative effect on periodontal tissue (see: Korean Patent Application No. 94-13606). The present inventors also found that the composition containing the thick leaf extract and the ginkgo leaf extract has an excellent effect on the periodontal disease in general, and has applied for a patent on the composition for treating the periodontal disease targeting them (reference: Korean Patent Publication No. 94- 14117) Subsequently, as a result of continuous research, jujube extract also showed excellent effect on the regeneration of periodontal tissue, and a patent application was also filed for the treatment of periodontal disease using jujube extract (see Korean Patent Application No. 95- 14541).
그러나 후박 추출물은 우수한 함염, 항균효과가 있으나 고용량으로 갈수록 치주조직세포의 활성을 저하시키는 단점이 있으며, 대추 추출물과 은행잎 추출물은 우수한 조직재생효과가 있으나 항균효과가 미흡하다는, 즉 치주질환 예방 및 치료에 관한 여러 가지 기전중에서 단지 일부의 경로를 통해서만 효과를 나타낸다는 단점이 있다. 이에 본 발명자들은 상기의 요건을 충족시키는 치주질환 치료제를 개발하고자 이러한 연구결과들을 기초로하여 대추 추출물과 후박 추출물을 다양한 비로 배합하여 치주질환에 대한 예방 및 치료효과를 검색하여 보았으며, 그 결과 놀랍게도 이들 두성분의 배합물이 특정배합비에서 각각의 성분을 단독으로 사용할 때 보다 월등히 우수한 상승적 치주질환 치료효과, 즉 우수한 조직재생 및 항균, 항염효과가 있으며, 특히 고용량에서 치주조직세포의 활성을 억제하는 후박 추출물의 단점을 극복하여 우수한 조직재생효과를 나타냄을 확인하고 본 발명을 완성하게 되었다.But thick extract has excellent salting and antimicrobial effect, but it has the disadvantage of lowering periodontal tissue cell activity at higher doses. Jujube extract and ginkgo biloba extract have excellent tissue regeneration effect but lack antibacterial effect, ie prevention and treatment of periodontal disease. Among the various mechanisms for, the disadvantage is that it only works through some pathways. Therefore, the present inventors searched for the prevention and treatment effect of periodontal disease by combining the jujube extract and the hindnut extract in various ratios based on the results of these studies in order to develop a treatment for periodontal disease satisfying the above requirements. The combination of these two components is superior to synergistic periodontal disease treatment effect, that is, excellent tissue regeneration, antibacterial and anti-inflammatory effect, when using each component alone in a specific combination ratio, especially thick pepper that inhibits the activity of periodontal tissue cells at high doses Overcoming the shortcomings of the extract was confirmed to exhibit an excellent tissue regeneration effect was completed the present invention.
따라서, 본 발명은 대추 추출물과 후박 추출물을 유효성분으로 함유하는 치주질환 예방 및 치료제 조성물에 관한 것이다.Therefore, the present invention relates to a periodontal disease prevention and treatment composition containing the jujube extract and the thick extract as an active ingredient.
본 발명의 대추 추출물과 후박 추출물의 조성물은 치주질환 예방 및 치료제로서 특정한 배합비에서 치주질환의 예방 및 치료에 광범위한 효과, 즉 (1) 약화되거나 파괴된 치주조직에 대한 우수한 재생효과와 (2) 치주조직을 파괴하는 염증반응을 억제하며, (3) 치주질환 원인균에 대한 우수한 항균효과를 나타낼 뿐 아니라, 이들의 효과는 대추 추출물과 후박 추출물이 갖고 있는 각각의 효과보다 훨씬 우수한 것이며, 또한 기존의 항생제 사용시의 문제점인 부작용도 없다는 장점을 제공한다.The composition of the jujube extract and the thick extract of the present invention have a wide range of effects on the prevention and treatment of periodontal disease at a specific compounding ratio, namely (1) excellent regeneration effect on weakened or destroyed periodontal tissue and (2) periodontal disease It inhibits inflammatory reactions that destroy tissues, and (3) exhibits excellent antimicrobial effect against the causative agent of periodontal disease, and their effect is much better than the effects of jujube extract and pepper extract. It provides the advantage that there is no side effect which is a problem in using.
본 발명의 조성물에서 후박 추출물로는 후박을 알콜, 바람직하게는 에탄올과 같은 저급알칸올로 추출하여 수득한 후박 엑기스를 사용하는데, 바람직하게는 주성분인 마그놀롤(magnolol)을 5.0% 이상, 호노키올(honokiol)은 1.0% 이상 함유하는 것을 사용한다. 또한, 대추 추출물로는 대추(Ziziphi fructus)를 알콜, 바람직하게는 에탄올과 같은 저급알칸올로 수욕상에서 추출한 후 감압하에서 농축하여 수득한 대추 엑기스를 사용한다.In the composition of the present invention, as a thick gourd extract, a thick gourd extract obtained by extracting a thick gourd with an alcohol, preferably a lower alkanol such as ethanol, preferably 5.0% or more of magnolol, which is a main component, and a honokiol (honokiol) is used to contain 1.0% or more. In addition, jujube extract obtained by extracting jujube (Ziziphi fructus) in a water bath with an alcohol, preferably a lower alkanol such as ethanol, and then concentrating under reduced pressure is used.
본 발명의 대추 추출물과 후박 추출물의 조성물은 각 성분을 단독으로 사용할 때 보다 치주질환에 대해 더 우수한 상승적 치료효과를 나타내는데, 특히 이러한 상승적 효과는 이하의 실험예를 통하여 입증되는 바와 같이 대추 추출물과 후박 추출물을 중량기준으로 1 : 6 내지 1 : 12 의 비, 특히는 1 : 8 내지 1 : 10의 비로 배합하는 경우에 가장 뚜렷하게 나타난다.The composition of the jujube extract and the thick gourd extract of the present invention exhibits a better synergistic treatment effect against periodontal disease than when each component is used alone. Particularly, this synergistic effect is obtained from the jujube extract and the thick gourd as demonstrated by the following experimental examples. It is most pronounced when the extract is blended in a ratio of 1: 6 to 1: 12, in particular in a ratio of 1: 8 to 1: 10.
따라서 본 발명의 조성물에서는 치주질환에 대한 상승적 치료효과를 극대화시키기 위하여 대추 추출물과 후박 추출물을 1 : 6 내지 1 : 12 의 중량비로, 특히 바람직하게는 1 : 8 내지 1 : 10 의 중량비로 배합하여 사용한다.Therefore, in the composition of the present invention, in order to maximize the synergistic treatment effect against periodontal disease, the jujube extract and the pear extract are combined in a weight ratio of 1: 6 to 1: 12, particularly preferably in a weight ratio of 1: 8 to 1: 10 use.
상기한 바와 같은 비로 대추 추출물과 후박 추출물이 배합된 본 발명의 조성물은 그대로 사용할 수도 있으나 바람직하게는 일반적으로 약제학적으로 허용되는 통상의 부형제를 첨가하여 약제학적 제제로 제형화시켜 이용할 수 있다. 이러한 목적으로 이용되는 제형으로는 정제, 연고제, 치약, 액제(가글), 분무제 등의 형태가 있는데, 예를 들면 본 발명의 조성물을 단독으로 치약조성물에 포함시키거나, 약제학적으로 허용되는 통상의 담체와 혼합하여 내복정제, 연고제 및 용액제로 제형화하여 치주질환의 예방 및 치료제로서 사용할 수 있다.The composition of the present invention in which the jujube extract and the thick extract are combined in the ratio as described above may be used as it is, but may be preferably formulated into a pharmaceutical preparation by adding a conventional pharmaceutically acceptable excipient. Formulations used for this purpose can be in the form of tablets, ointments, toothpastes, solutions (gagle), sprays, and the like. For example, the composition of the present invention may be included alone in a toothpaste composition, or a pharmaceutically acceptable It can be mixed with a carrier and formulated into an internal appetite, ointment and solution to be used as a preventive and therapeutic agent for periodontal disease.
또한 통상적인 가글제에 포함시켜 양치질후에 입안을 헹구거나, 분사제를 포함시켜 압축용기에 포장한 분무제로서 치주질환 부위에 분무할 수도 있고 치약성분에 포함시켜 계속적으로 장기간 동안 사용함으로써 치주질환의 예방 및 치료효과를 얻을 수도 있다.It is also included in a conventional gargle to rinse your mouth after brushing your teeth, or it can be sprayed onto a periodontal disease site as a spray containing a propellant and packed in a compressed container. You can also get a therapeutic effect.
본 발명에 따르는 조성물의 유효용량은 사용목적이나 치료하고자 하는 치주질환의 중증도, 이용하는 제형 등에 따라 달라질 수 있으나, 일반적으로는 성인에게 대추 추출물과 후박 추출물의 배합물로서 1일에 50mg내지 1g 특히는 100내지 500mg의 양으로 사용하는 것이 바람직하다.The effective dose of the composition according to the present invention may vary depending on the purpose of use or the severity of the periodontal disease to be treated, the dosage form to be used, etc., but in general, 50 mg to 1 g per day as a combination of jujube extract and hummus extract, especially 100 Preference is given to using in amounts of from 500 mg.
전체 조성물중의 대추 추출물과 후박 추출물의 배합물의 함량범위는 사용목적에 따라 다양하게 할 수 있으나, 농도가 너무 낮으면 효과가 급격히 떨어지고, 너무 높으면 대추 추출물 및 후박 추출물의 착색으로 인하여 상품성이 떨어지므로, 상기한 바와 같은 대추 추출물과 후박 추출물의 배합물의 유효용량 범위를 고려하여 정제의 경우에는 단위정제당 상기와 같은 비로 배합된 대추 추출물과 후박 추출물의 배합몰 50mg 내지 250mg을 함유하도록 제형화시키는 것이 바람직하고 연고제, 액제(가글), 치약, 분무제의 경우에는 배합몰이 0.2 내지 5.0중량%의 비로 함유되도록 제형화시키는 것이 바람직하다The content range of the combination of the jujube extract and the thick gourd extract in the whole composition may vary depending on the purpose of use, but if the concentration is too low, the effect drops sharply, and if it is too high, the commerciality is poor due to the coloring of the jujube extract and the thick gourd extract. In consideration of the effective dose range of the combination of the jujube extract and the hind extract as described above, in the case of tablets, it is preferable to formulate to contain 50 mg to 250 mg of the combined moles of the jujube extract and the hind extract in the above ratio per unit tablet. In the case of ointments, liquids (gargles), toothpastes, and sprays, it is preferable to formulate the compounding molar in a ratio of 0.2 to 5.0% by weight.
한편, 대추 추출물과 후박 추출물은 마우스와 랫트에서 경구투여시 급성 독성의 기준치의 LD50(50% 치사량 ) 이 각각 5000mg/Kg 이상으로 나타나 안전한 약물임이 밝혀졌다.On the other hand, jujube extract and hubac extract were LD 50 (50% lethal dose) of the standard value of acute toxicity upon oral administration in mice and rats, respectively.
본 발명의 조성물에는 또한 치주질환의 치료 및 예방에 효과가 있는 것으로 공지되어 있는 생약성분, 예를 들면 은행잎 추출물, 몰약, 상백피 추출물, 상귀나리아 추출물, 옥수수 추출물 등의 성분을 추가로 포함시켜 목적하는 효과를 증가시킬 수도 있다.The composition of the present invention may further include herbal ingredients known to be effective in the treatment and prevention of periodontal disease, for example, ginkgo biloba extract, myrrh, lettuce extract, lettuce extract, corn extract and the like. You can also increase the effect.
본 발명은 이하의 실시예, 실험예 및 조성예에 의해 더욱 구체적으로 설명되나, 본 발명이 이들에 의해 어떤 식으로든 제한되는 것은 아니다.The present invention is explained in more detail by the following examples, experimental examples and composition examples, but the present invention is not limited in any way by these.
[실시예 1 : 후박으로부터 후박 추출물의 제조]Example 1 Preparation of Thick Pepper Extract from Thick Pepper
후박 (Magnoliae cortex) 500g을 얇게 절단하고 70% 에탄올 2.5ℓ씩을 사용하여 수욕상에서 환류하에 3시간씩 2회 추출하고, 추출물을 합하여 여과한 다음 여액을 농축시켜 후박 추출물 60g을 수득하였다.500 g of thin gourd (Magnoliae cortex) was thinly cut and extracted twice with reflux in a water bath using 2.5 L of 70% ethanol twice for 3 hours, the extracts were combined and filtered, and the filtrate was concentrated to give 60 g of gourd extract.
[실시예 2 : 대추로부터 대추 추출물의 제조]Example 2 Preparation of Jujube Extract from Jujube
대추(Zizyphi fructus) 300g을 70% 에탄올 1.5ℓ씩을 사용하여 수욕상에서 환류하에 3시간씩 2회 추출하고, 추출물을 합하여 여과한 다음 여액을 농축시켜 대추 추출물 140g을 수득하였다.300 g of Zyzyphi fructus was extracted twice with reflux in a water bath using 1.5 L of 70% ethanol, and the extracts were combined and filtered, and the filtrate was concentrated to obtain 140 g of jujube extracts.
본 발명의 대추 추출물과 후박 추출물의 배합조성물은 통상적인 약제학적 방법으로, 예를 들면 정제, 연고제, 치약 액제 (가글), 분무제의 제형으로 제조할 수 있으며, 대추 추출물과 후박 추출물의 배합비는 하기의 실험예들을 종합하여 바람직하게는 1:6 내지 1 : 12 중량비, 특히 바람직한 것은 1 : 8 내지 1 : 10 중량비이며, 그 조성물의 예를 들면 다음과 같다.The combination composition of the jujube extract and the thick extract of the present invention may be prepared by a conventional pharmaceutical method, for example, in the form of tablets, ointments, toothpaste liquids (gagle), sprays, and the combination ratio of the jujube extract and the thick extract is as follows. In combination with the experimental examples of preferably 1: 6 to 1: 12 by weight, particularly preferably 1: 8 to 1: 10 by weight, for example of the composition is as follows.
[조성예 1 : 필름 코팅정 - 1 정 (600mg)중][Composition Example 1: Film Coated Tablet-1 Tablet (600mg)]
대추 추출물 20mgJujube Extract 20mg
후박 추출물 200mgThick Extract 200mg
유당 355mgLactose 355mg
히이드록시프로필셀룰로오스 5mgHydroxypropyl Cellulose 5mg
스테아린산마그네슘 3mgMagnesium Stearate 3mg
글리세린 2mgGlycerin 2mg
히드록시프로필메틸셀룰로오스 15mgHydroxypropylmethylcellulose 15mg
상기의 성분들을 이용하여 통상적인 정제의 제조방법에 따라 정제를 제조한다.Tablets are prepared according to the conventional method for preparing tablets using the above ingredients.
[조성예 2 : 연고제 (수치는 중량%)][Composition Example 2: Ointment (Value by Weight)]
대추 추출물 0.04Jujube Extract 0.04
후박 추출물 0.32Thick Extract 0.32
카르복시비닐폴리머 7.00Carboxyvinyl Polymer 7.00
글리세롤 30.00Glycerol 30.00
페퍼민트오일 0.006Peppermint Oil 0.006
프로필렌글리콜 30.00Propylene Glycol 30.00
정제수를 가하여 100으로 한다.Add purified water to make 100.
상기 성분들을 통상적인 연고제의 제조방법으로 혼합하여 연고제를 제조한다.The components are mixed by a conventional method for preparing an ointment to prepare an ointment.
[조성예 3 : 치약 (수치는 중량%)][Composition Example 3: Toothpaste (Value by Weight)]
대추 추출물 0.04Jujube Extract 0.04
후박 추출물 0.40Thick Extract 0.40
알루미나 45.00Alumina 45.00
프로필렌글리콜 10.00Propylene Glycol 10.00
카르복시메틸셀룰로오스나트륨 2.00Carboxymethylcellulose Sodium 2.00
스테비오사이드 0.30Stevioside 0.30
라우릴황산나트륨 1.00Sodium Lauryl Sulfate 1.00
페퍼민트 0.50Peppermint 0.50
정제수를 가하여 100으로 한다.Add purified water to make 100.
상기 성분들을 통상적인 치약 제조방법으로 혼합하여 치약을 제조한다.Toothpaste is prepared by mixing the above components in a conventional toothpaste manufacturing method.
[조성예 4 : 용액제 (수치는 중량%)][Composition Example 4: Solution (Weight Value)]
대추추출물 0.08Jujube extract 0.08
후박추출물 0.96Thick Extract 0.96
폴리에틸렌글리콜 7.00Polyethylene Glycol 7.00
에탄올 5.00Ethanol 5.00
페퍼민트오일 0.06Peppermint Oil 0.06
정제수를 가하여 100으로 한다.Add purified water to make 100.
상기 성분들을 통상적인 액제 제조방법으로 혼합하여 용해시키고, pH를 5.0으로 조절하여 용액제를 제조한다.The components are mixed and dissolved in a conventional liquid preparation method, and a pH is adjusted to 5.0 to prepare a solution.
[조성예 5 : 분무제 (수치는 중량%)]COMPOSITION EXAMPLE 5: Atomizer (Value by Weight)]
대추 추출물 0.04Jujube Extract 0.04
후박 추출물 0.24Thick Extract 0.24
트리클로로모노플루오로메탄 40.00Trichloromonofluoromethane 40.00
디클로로디플루오로메탄 45.00Dichlorodifluoromethane 45.00
페퍼민트오일 0.15Peppermint Oil 0.15
에탄올 6.00Ethanol 6.00
폴리에틸렌글리콜 8.65Polyethylene Glycol 8.65
상기 성분들을 통상적인 분무제 제조방법으로 혼합하고 압축용기에 충전 포장하여 분무제를 제조한다.The components are mixed by a conventional spray preparation method and packed into a compression container to prepare a spray.
[실험예 : 대추 추출물 및 후박 추출물의 배합비 결정을 위한 실험]Experimental Example: Experiment for Determination of Mixture Ratio of Jujube Extract and Thick Leaf Extract
[실험예 1 : 치은섬유아세포 활성도 측정]Experimental Example 1: Measurement of gingival fibroblast activity
대추 추출물과 후박 추출물의 배합물을 함유하는 본 발명의 조성물에서 최적의 조직재생효과를 나타내는 배합비를 위하여 조성물중의 두성분의 배합비를 변화시키면서 이들 배합물이 치은섬유아세포 활성에 미치는 영향을 측정하였다. 이 실험을 위한 치은섬유아세포는 서울대학병원에 치아의 교정치료를 위하여 내원한 환자를 대상으로 제일 소구치의 치은부위를 채취하여 이용하였다. 치은부위의 채취직전에 큐렛을 이용하여 치석 및 치태 등을 제거하고 생리식염수로 수회 세척하고, 국소마취를 실시한 후에 치간부위에 내사면 절제를 가하고 정상 치은조직을 채취하였다. 채취한 조직편을 페니실린 100U/㎖와 스트렙토마이신 100㎍/㎖ 및 100% FBS가 첨가된 α-MEN(GIBCO, In., Grand island, N,Y., U.S.A.) 배지중에서 배양하였으며, 3일 간격으로 배지를 동량의 새로운 배지로 교환해주면서 5회 계대배양시켰다. 배양시에 습도는 95%, 온도는 37C를 유지하면서 95% 공기와 5% CO2를 계속 공급하였다. 계대배양한 치은섬유아세포를 0.25% 트립신-EDTA(에틸렌디아민테트라아세테이트)용액으로 처리한 후 1200rpm에서 원심분리하여 배양액중의 세포부유액을 얻고, 표준혈구계산기를 이용하여 96-웰 플레이트에 웰당 세포수가 1×105개가 되도록 접종한 후 5% CO2, 37℃에서 1일 동안 배양하였다. 다음날 배양액을 신선한 배양액으로 교환해 주고, 이틀째 되는 날 배양액을 제거한 후 HBSS(Hank's Balanced salt solution)로 세척하였다. 양성대조용 실험제제인 혈소판 유도성장인자(PDGF-BB(Genzyme, Co., Cambridge, MA., U.S.A.)는 증류수를 용매로 하고, 후박 추출물은 에탄올(EtOH)로, 대추 추출물 및 은행잎 추출물은 디메틸설폭사이드(DMSO)를 용매로 하여 용해시킨 다음, 이들을 각 실험물질의 농도가 하기 표에 언급된 바와 같은 농도가 되도록 배양액에 가하여 습도 95%, 온도 37℃를 유지하면서 95% 공기와 5% CO2를 계속 공급하면서 24시간 동안 배양하였다. 배양이 끝난 후에 생리식염수에 용해된 MTT(메틸 티아졸-2-일-2,5-디페닐테트라졸리움 브로마이드, Sigma Co., St, Louis, M.O., U.S.A.) 용액 50㎕ 씩을 각 웰에 가하고 상기와 동일한 조건하에서 4시간 동안 더 배양한 후 MTT용액을 감압하에서 여과하여 제거하고, 생성된 포르마존(formazon) 결정을 용해시키기 위해 각 웰에 DMSO 50㎕씩을 첨가하였다. 플레이트를 잘 흔든 후에 ELISA판독기 (ELISA reader, Thermo max, molecular devices, Menlo Park C.A., U.S.A.)로 570㎚에서 흡광도를 측정하였다. 이 실험에서 대조군에는 매 실험마다 시험물질이 첨가되지 않은 α-MEN 배지 만을 사용하였다. 모든 실험결과는 대조군에 대한 백분율로 계산하여 표 1 내지 3에 나타내었다.The effect of these formulations on the gingival fibroblast activity was varied while varying the blending ratios of the two components in the composition of the present invention containing the combination of jujube extract and the hulled extract. The gingival fibroblasts for this experiment were collected from the gingival area of the first premolar from patients who visited Seoul National University Hospital for orthodontic treatment. Immediately before the gingival area was collected, calculus and plaque were removed using a curette, washed several times with physiological saline, local anesthesia was applied to the interdental area, and normal gingival tissue was collected. The collected tissue pieces were incubated in α-MEN (GIBCO, In., Grand island, N, Y., USA) medium containing 100 U / ml penicillin, 100 µg / ml streptomycin and 100% FBS. Five passages were made while replacing the medium with the same amount of fresh medium. During the cultivation, 95% air and 5% CO 2 were continuously supplied while maintaining a humidity of 95% and a temperature of 37C. Substituted gingival fibroblasts were treated with 0.25% trypsin-EDTA (ethylenediaminetetraacetate) solution and centrifuged at 1200 rpm to obtain cell suspension in the culture medium, and the number of cells per well in a 96-well plate using a standard hemocytometer. Inoculated to 1 × 10 5 and incubated for 1 day at 5% CO 2 , 37 ℃. The next day the culture medium was replaced with fresh culture medium, and the second day the culture medium was removed and washed with HBSS (Hank's Balanced salt solution). Platelet-induced growth factor (PDGF-BB (Genzyme, Co., Cambridge, MA., USA)), a positive control agent, was used as distilled water as a solvent, and the extract was ethanol (EtOH). Jujube extract and ginkgo leaf extract were dimethyl. After dissolving sulfoxide (DMSO) as a solvent, these were added to the culture solution so that the concentration of each test substance was as mentioned in the following table, and maintained with 95% air and 5% CO while maintaining a humidity of 95% and a temperature of 37 ° C. The cells were incubated for 24 hours while continuing to supply 2. MTT (methyl thiazol-2-yl-2,5-diphenyltetrazolium bromide, Sigma Co., St, Louis, MO, dissolved in physiological saline after incubation was continued. USA) 50 μl of solution was added to each well and further incubated for 4 hours under the same conditions as above, and the MTT solution was filtered off under reduced pressure, and 50 μl of DMSO was added to each well to dissolve the resulting formazon crystals. Add each plate. Afterwards, the absorbance was measured at 570 nm using an ELISA reader (ELISA reader, Thermo max, molecular devices, Menlo Park CA, USA) In this experiment, only the α-MEN medium without test substance was used for each experiment. All experimental results are shown in Tables 1 to 3 calculated as a percentage of the control group.
상기 표 1에 기재된 결과로부터, 대추 추출물은 용량이 증가할수록 세포활성도를 증가시키며, 10㎍/㎖이상의 농도에서 최대효과를 나타내는 것을 알 수 있다.From the results described in Table 1, the jujube extract increases the cell activity as the dose is increased, it can be seen that the maximum effect at a concentration of 10 μg / ㎖ or more.
상기 표 2에 기재된 결과로부터, 후박 추출물은 용량이 증가할수록 세포활성을 감소시키는 것을 알 수 있다.From the results described in Table 2, it can be seen that the thick gourd extract decreases cellular activity as the dose is increased.
상기 표 1 내지 3에 기재된 결과로부터 알수 있는 바와 같이, 대추 추출물과 후박 추출물을 각각 단독으로 사용하는 경우에는, 대추 추출물만이 치은섬유아세포의 활성을 증가시키는 효과가 있고 후박 추출물은 오히려 치은섬유아세포의 활성을 억제하나, 대추 추출물과 후박 추출물을 배합한 조성물을 사용하는 경우에는 이들의 배합비가 중량기준으로 1 : 6 내지 1 : 12 인 경우에 대추 추출물을 단독으로 사용할 때 보다 훨씬 더 우수한 치은섬유아세포 활성효과를 나타내었으며, 특히 중량기준으로 1 : 8 내지 1 : 10 의 배합비에서 치은섬유아세포의 활성이 크게 증가하였다. 이는 대추 추출물과 후박 추출물을 배합하여 사용함으로써 후박 추출물과 대추 추출물의 상호작용에 의하여 치은섬유아세포의 활성증가효과가 나타나는 결과이다. 또한 이러한 증가된 효과는 기존에 치은섬유아세포의 활성을 증가시키는 것으로 알려져 있는 대표적인 성분인 PDGF 및 은행잎 추출물과 후박 추출물의 조성물의 효과 보다 훨씬 우수한 것임을 알 수 있다. 따라서 본 발명에 따르는 후박 추출물과 대추 추출물의 조성물은 특정 배합비에서 각각의 성분을 단독으로 사용할 때 보다 상승효과가 있음을 알 수 있고, 또한 우수한 치주질환 치료제임이 명백함을 알 수 있다.As can be seen from the results described in Tables 1 to 3 above, when jujube extract and thick extract are used alone, only jujube extract has the effect of increasing the activity of gingival fibroblasts and the thick extract is rather gingival fibroblast In the case of using a composition comprising a jujube extract and a thick extract extract, but the combination ratio of the weight ratio of 1: 6 to 1: 12 by weight is much better than the gingival extract when using the jujube extract alone It showed a blast activity, especially the activity of gingival fibroblasts was significantly increased at a weight ratio of 1: 8 to 1: 10 by weight. This is the result of increasing the activity of the gingival fibroblasts by the combination of jujube extract and jujube extract by using a combination of jujube extract and hulhu extract. In addition, this increased effect can be seen that far better than the effect of the composition of PDGF and ginkgo biloba extract and thick extract which are known to increase the activity of gingival fibroblasts. Therefore, it can be seen that the composition of the extract and jujube extract according to the present invention is more synergistic than the use of each component alone in a specific compounding ratio, and also clear that it is an excellent periodontal disease treatment.
[실험예 2 : 항염효과 측정]Experimental Example 2: Anti-inflammatory effect measurement
본 발명에 따르는 대추 추출물과 후박 추출물의 조성물의 항염효과는 시험관내 시험으로 치은섬유아세포의 PGE생산억제효과를 측정함으로써 확인하였다. 5회 내지 7회 계대 배양된 치은섬유아세포를 24-웰 플레이트의 각웰중의 1% 항생제, 1% FBS 가 포함된 α-MEM(GIBCO, In. Grand island, N.Y.,U.S.A.) 배지 1㎖에 10 세포의 농도로 분주한 후 rHUIL-1β(Genzyme, Co.,Cambridge,M.A.,U.S.A.) 1ng/㎖을 첨가하여 PGE생성을 유도하였다. 여기에 시험물질로서 후박 추출물은 에탄올(EtOH)로, 대추 추출물 및 은행잎 추출물은 디메틸설폭사이드(DMSO)를 용매로 하여 용해시킨 다음, 이들을 각 실험물질의 농도가 하기 표에 언급된 바와 같은 농도가 되도록 각 웰의 배양액에 가하고, 어떠한 시험물질도 첨가 하지 않은 웰을 대조군으로하여 5% CO, 37℃에서 48 시간 동안 무균적으로 배양하였다. 배양이 끝난 후에, 각 웰의 배지를 수집하여 배지내의 PGE를 효소면역분석시스템(PGEcnzymc immunoassay system, Amersham, In. Buckinghamshirc, U.K.)을 이용하여 ELISA 판독기로 450nm에서 비색정량하였으며, 그 결과를 표 4내지 6에 나타내었다.The anti-inflammatory effect of the composition of the jujube extract and the thick extract according to the present invention was confirmed by measuring the inhibitory effect of PGE production of gingival fibroblasts by an in vitro test. Five to seven passages of gingival fibroblasts were placed in 1 ml of α-MEM (GIBCO, In. Grand island, N.Y., U.S.A.) medium containing 1% antibiotic, 1% FBS in each well of a 24-well plate. After dispensing at the concentration of cells, 1 ng / ml of rHUIL-1β (Genzyme, Co., Cambridge, M.A., U.S.A.) was added to induce PGE production. Here, as a test substance, the thick leaf extract was dissolved in ethanol (EtOH), the jujube extract and the ginkgo biloba extract were dissolved in dimethyl sulfoxide (DMSO) as a solvent, and the concentrations of the respective test substances were as shown in the following table. Each well was added to the culture solution, and the wells without addition of any test substance were sterilely incubated for 48 hours at 37% with 5% CO. After the incubation, the medium of each well was collected and the PGE in the medium was colorimetrically determined at 450 nm using an ELISA reader using an enzyme immunoassay system (PGEcnzymc immunoassay system, Amersham, In. Buckinghamshirc, UK). To 6 are shown.
상기 표 4에 기재된 결과로부터, 대추 추출물은 용량이 증가할수록 PGE의 생산을 억제하며, 10㎍/㎖ 이상의 농도에서 최대효과를 나타내는 것을 알 수 있다.From the results shown in Table 4, jujube extract inhibits the production of PGE as the dose is increased, it can be seen that the maximum effect at a concentration of 10 µg / ㎖ or more.
상기 표 5에 기재된 결과로부터, 후박 추출물은 용량이 증가할수록 PGE의 생산을 억제하며, 그 효과는 100㎍/㎖ 이상에서 최대인 것을 알 수 있다.From the results described in Table 5, the thick gourd extract inhibits the production of PGE as the dose is increased, the effect can be seen that the maximum at 100 μg / ㎖ or more.
상기 표 4내지 6의 결과로부터 알 수 있는 바와 같이, 대추 추출물과 후박 추출물을 각각 단독으로 사용하는 경우에 대추 추출물은 염증반응을 매개하는 PGE의 생성을 미약하게 억제하고 후박 추출물은 PGE의 생성을 상당한 수준으로 억제한다. 그러나, 대추 추출물과 후박 추출물의 조성물을 사용한 경우에는 중량을 기준으로 하여 1 : 6 내지 1 : 12 의 배합비에서 후박 추출물만을 단독으로 사용한 경우에 비하여 월등히 우수한 PGE생성억제효과를 나타내었으며, 그외의 배합비에서는 효과가 감소하였다. 이러한 결과는 후박 추출물과 대추 추출물을 배합함으로서 대추 추출물에 의하여 후박 추출물의 PGE생성억제효과가 증가됨으로써 나타나는 것이다. 또한, 이러한 증가된 효과는 기존에 치주질환 치료에 가장 우수한 것으로 알려져 있는 은행잎 추출물과 후박 추출물의 조성물에 의한 효과보다도 월등히 더 우수한 것이다. 따라서 본 발명에 따르는 후박 추출물과 대추 추출물의 조성물은 특정 배합비에서 각각의 성분을 단독으로 사용하는 경우에 비해 치주질환에 대해 명백한 상승적 효과가 있음을 알 수 있고, 우수한 치주질환 치료제임을 알수 있다.As can be seen from the results of Tables 4 to 6, the jujube extract slightly inhibits the production of PGE that mediates the inflammatory response when jujube extract and the pepper extract are used alone, and the pepper extract extracts the production of PGE. Suppresses to a significant level. However, in the case of using the composition of jujube extract and thick gourd extract showed a significantly superior PGE production inhibitory effect compared to the case of using only the thick gourd extract alone in the blending ratio of 1: 6 to 1: 12, and other combination ratio The effect was reduced at. These results are shown by increasing the PGE production inhibitory effect of the extract of jujube extract by jujube extract and jujube extract. In addition, this increased effect is far superior to the effect of the composition of the ginkgo biloba extract and thick leaf extract that is known to be the best treatment for periodontal disease. Therefore, the composition of the extract and jujube extract according to the present invention can be seen that there is a clear synergistic effect on periodontal disease compared to the case of using each component alone in a specific compounding ratio, it can be seen that it is an excellent periodontal disease treatment.
[실험예 3 : 항균효과 측정]Experimental Example 3: Antibacterial Effect Measurement
본 발명에 따른 대추 추출물과 후박 추출물의 조성물의 항균효과를 측정하기 위하여 치주병원균으로서 미국 뉴욕주립대학교 치과대학에서 기증받은 혐기성그람음성균인 포르피로모나스 깅기발리스(Porphyromonas gingivalis) W50, 프레보텔라 인터메디아(Prevotella intermedia) ATCC 25611 및 통기성 그람음성균인 악티노바실러스 악티노미세템코미탄스(Actinobacillus actinomycetemcomitans) Y4를 사용하여 다음과 같은 실험을 수행하였다.Porphyromonas gingivalis (Worphyromonas gingivalis) W50, which is a donor of the periodontal pathogen, which was donated by the University of New York State University of Dentistry, to measure the antimicrobial effect of the extract of jujube extract and the pear extract according to the present invention The following experiments were performed using Prevotella intermedia ATCC 25611 and the breathable Gram-negative bacterium Actinobacillus actinomycetemcomitans Y4.
포르피로모나스 깅기발리스 W50(PG) 및 프레보텔라 인터메디아 ATCC 25611(PI) 은 헤민 5㎕ 및 메나디온 0.5㎕이 함유된 트립티카제 소이 아가(trypti-case soy agar) 한천혈액배지에 접종하여 37℃, 10% CO10% H및 80% N가든 혐기성 배양기에서 순수배양하였고, 악티노바실러스 악티노미세템코미탄스 Y4 가 (AA)는 트립티카제 소이 아가 한천혈액배지에 접종하여 통기성으로 10% CO가 든 세균배양기에서 순수배양하였다. 각각 4 내지 7 일간 순수배양된 균들을 각각 트립티카제 소이 브로스에 접종하여 48 내지 72 시간 동안 상기한 바와 같은 혐기성 및 통기성 배양기에서 배양하여 세균수가 10 세포/㎖가 되도록 하였다. 이들 배양된 세균들은 다접종기(multi-inoculator)를 이용하여 각 실험물질이 하기 표에 언급된 바와 같은 농도로 배합된 혈액한천배지에 접종하였다. 이들 배지를 3내지 5일 동안 10% CO, 10% H및 80% N가 혼합된 혐기성 배양기에서 37℃에서 배양한 후 세균의 성장유무를 육안으로 확인하여 각 균주의 성장에 대한 최소억제농도(Minimum Inhibitory Concentration, MIC)를 하기 표 7에 나타내었다.Porphyromonas Gingivalis W50 (PG) and Prebotella intermediary ATCC 25611 (PI) were inoculated into trypti-case soy agar agar medium containing 5 μl of hemin and 0.5 μl of menadione. Was incubated in an anaerobic incubator at 37 ° C., 10% CO 10% H and 80% N, and Actinobacillus actinomycetemcomitans Y4 (AA) was inoculated in trypticase soy agar agar blood medium and breathable 10 Pure culture was carried out in a bacterial incubator containing% CO. Each of the inoculated bacteria cultured for 4 to 7 days in trypticase soy broth was incubated in the anaerobic and breathable incubators as described above for 48 to 72 hours, respectively, Cells / ml. These cultured bacteria were inoculated in a blood agar medium in which each test substance was formulated at a concentration as mentioned in the following table using a multi-inoculator. These mediums were incubated at 37 ° C. in an anaerobic incubator mixed with 10% CO, 10% H and 80% N for 3 to 5 days, and then visually checked for the growth of bacteria. Minimum Inhibitory Concentration (MIC) is shown in Table 7 below.
상기 표 7의 결과로부터 알수 있는 바와 같이, 실험예 1의 치은섬유아세포 활성효과와 실험예 2의 항염효과 측정실험에서 상승효과를 나타내는 것으로 확인된 대추 추출물과 후박 추출물의 조성물은 중량을 기준으로하여 1 : 6 내지 1 : 12 의 배합비에서 향균효과도 각각을 단독으로 사용한 경우에 비해 월등히 우수한 것으로 나타났다.As can be seen from the results of Table 7, the composition of the jujube extract and the pear extract, which were found to have a synergistic effect in the gingival fibroblast activity effect of Experimental Example 1 and the anti-inflammatory effect measurement Experiment of Experimental Example 2, based on the weight It was shown that the antibacterial effect was also excellent in the combination ratio of 1: 6 to 1:12 compared with the case where each was used alone.
이는 대추 추출물 자체는 항균효과가 거의 없으나 후박 추출물과 배합함으로써 대추 추출물이 후박 추출물의 항균효과를 증가시킴으로써 나타나는 결과이다. 또한 이러한 증가된 효과는 기존에 치주질환 치료에 가장 우수한 것으로 확인된 은행잎 추출물과 후박 추출물의 조성물의 효과보다도 더 우수한 것이다. 따라서, 본 발명의 후박 추출물과 대추 추출물의 조성물은 각각의 성분을 단독으로 사용하는 경우에 비해 명백한 상승적 항균효과가 있음이 명백하다.This jujube extract itself has little antimicrobial effect, but it is the result of jujube extract by increasing the antimicrobial effect of the extract after mashing with the extract. In addition, this increased effect is better than the effect of the composition of the ginkgo biloba extract and the thick leaf extract that was previously found to be the best treatment for periodontal disease. Therefore, it is clear that the composition of the thick gourd extract and the jujube extract of the present invention have a clear synergistic antimicrobial effect compared to the case of using each component alone.
상기 실험예에서 입증되는 바와 같이, 본 발명의 대추 추출물과 후박 추출물의 조성물은 중량을 기준으로 하여 1 : 6내지 1 : 12의 배합비에서 각각의 성분을 단독으로 사용하는 경우에 나타나는 편중된 효과를 극복하여 치주질환 치료에 관한 다양한 치료효과를 나타내었고, 이러한 효과는 각각의 성분을 단독으로 사용할 때 보다 월등히 우수한 상승적 효과로 나타났다.As demonstrated in the above experimental example, the composition of the jujube extract and the thick extract of the present invention has a biased effect that appears when each component is used alone at a mixing ratio of 1: 6 to 1: 12 based on the weight. Overcoming and showing various therapeutic effects on the treatment of periodontal disease, this effect was shown to be a much better synergistic effect than when using each component alone.
[실험예 4 : 안정성 시험]Experimental Example 4: Stability Test
상기 조성예 1내지 5에 따라 제조한 제제의 안정성을 알아보기 위하여 각 제제를 후술하는 보관조건하에서 보관한 다음에 각 제제중의 후박 추출물의 마그놀롤의 함량을 고속액체크로마토그라피(HPLC)법으로 UV 검출기의 254nm에서 분석하여 그 결과를 다음 표 8에 나타내었다.In order to determine the stability of the formulations prepared according to Composition Examples 1 to 5, each formulation was stored under the storage conditions described below, and then the content of magnolol in the thick extract of each formulation was determined by high performance liquid chromatography (HPLC) method. Analysis at 254 nm of the UV detector and the results are shown in Table 8.
[보관조건][Storage Conditions]
-시험재료 : 상기 조성예 1내지 5에 따라 제조한 시료를 유리병 또는 압축용기에 넣고 마개를 하여 밀봉시킨 후에 판지상자에 넣은 것을 사용하였다.-Test material: The sample prepared according to Composition Examples 1 to 5 was put in a glass bottle or a compression container and sealed by sealing, then used in a cardboard box.
-보관조건 : 40℃ (± 10℃)Storage condition: 40 ℃ (± 10 ℃)
단 조성예 5의 분무제는 실온에서 보관하였다.However, the spray agent of composition example 5 was stored at room temperature.
-측정시기 : 제조직후, 2개월후, 4개월후, 6개월후Measurement period: Immediately after manufacture, after 2 months, after 4 months, after 6 months
-시험항목 :-Test Items :
조성예 1 (필름코팅정) : 성상, 붕해(인공위액), 함량Composition Example 1 (Film Coated Tablet): Appearance, Disintegration (Artificial Gas Solution), Content
조성예 2 (연고제) : 성상, 함량Composition Example 2 (Ointment): Appearance, Content
조성예 3 (치 약) : 성상, pH(10% 현탁액), 함량Composition Example 3 (Toothpaste): Appearance, pH (10% suspension), Content
조성예 4 (용액제) : 성상, pH, 함량Composition Example 4 (Solution Agent): Appearance, pH, Content
조성예 5 (분무제) : 함량Composition Example 5 (Atomizer): Content
상기 표 8에 기재된 결과로부터 알 수 있는 바와 같이, 안정성 시험결과 40℃에서 6개월후의 정제, 연고제, 치약, 용액제, 분무제에서의 성상의 변화가 거의 없고, 후박 추출물중의 마그노롤의 함량도 제조직후에 비해 95%이상을 나타내어 안정된 제제로 판단되며 산업화하는데 안정성의 문제가 없는 것으로 사료된다.As can be seen from the results shown in Table 8, the stability test results show little change in the properties of tablets, ointments, toothpastes, solutions, and sprays after 6 months at 40 ° C, and the content of magnolol in the thick extract It is considered to be a stable product because it shows more than 95% compared to immediately after manufacture, and there is no problem of stability in industrialization.
Claims (7)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960008393A KR0176015B1 (en) | 1996-03-26 | 1996-03-26 | Periodontal disease prevention and treatment composition |
| PCT/KR1997/000048 WO1997035599A1 (en) | 1996-03-26 | 1997-03-26 | Composition for prevention and treatment of periodontal diseases |
| AU21800/97A AU2180097A (en) | 1996-03-26 | 1997-03-26 | Composition for prevention and treatment of periodontal diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960008393A KR0176015B1 (en) | 1996-03-26 | 1996-03-26 | Periodontal disease prevention and treatment composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970064617A KR970064617A (en) | 1997-10-13 |
| KR0176015B1 true KR0176015B1 (en) | 1999-03-20 |
Family
ID=19454008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960008393A Expired - Lifetime KR0176015B1 (en) | 1996-03-26 | 1996-03-26 | Periodontal disease prevention and treatment composition |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR0176015B1 (en) |
| AU (1) | AU2180097A (en) |
| WO (1) | WO1997035599A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101704589B1 (en) * | 2016-07-12 | 2017-02-08 | 주식회사 뉴트라팜텍 | Composition comprising extracts of Magnolia flower and Magnolia officinlis for preventing or treating periodentitis as an active ingredient |
| KR102621090B1 (en) | 2023-08-20 | 2024-01-23 | 주식회사 구강닥터 | Drinking mouthwash composition capable of deodorizing and preventing tooth decay and its manufacturing method |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11279039A (en) * | 1998-03-31 | 1999-10-12 | Saiseido Yakuhin Kk | Composition for oral cavity |
| WO2001082922A1 (en) * | 2000-04-27 | 2001-11-08 | The Procter & Gamble Company | Oral compositions comprising polyphenol herbal extracts |
| US6500409B1 (en) * | 2000-05-10 | 2002-12-31 | Colgate Palmolive Company | Synergistic antiplaque/antigingivitis oral composition |
| KR100361880B1 (en) * | 2000-06-22 | 2002-11-23 | 동국제약 주식회사 | Compositions of containing titrated extract of the unsaponifiable fraction of Zea Mays L. and extract of Magnoliae Cortex for prevention and treatment of periodontal disease |
| CN102008000A (en) * | 2002-06-25 | 2011-04-13 | Wm.雷格利Jr.公司 | Breath freshening and oral cleansing product with magnolia bark extract |
| US7595065B2 (en) * | 2002-06-25 | 2009-09-29 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing products with synergistic combinations of magnolia bark extract and essential oils |
| US7347985B2 (en) | 2002-06-25 | 2008-03-25 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract |
| US7632525B2 (en) | 2002-06-25 | 2009-12-15 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents |
| US8900644B2 (en) | 2004-12-22 | 2014-12-02 | Colgate-Palmolive Company | Oral care compositions containing compounds from magnolia and hops extracts |
| US20060140885A1 (en) * | 2004-12-29 | 2006-06-29 | Abdul Gaffar | Method of reducing oral tissue inflammation using magnolia extract |
| CA2631501A1 (en) | 2005-12-02 | 2007-06-07 | Gic Innovations Company | Confectionary compositions with magnolia bark extract |
| WO2007067340A1 (en) * | 2005-12-02 | 2007-06-14 | Gic Innovations Company | Chewable compositions with fast release magnolia bark extract |
| WO2007064519A1 (en) * | 2005-12-02 | 2007-06-07 | Gic Innovations Company | Vehicles for oral care with magnolia bark extract |
| BRPI0810435A2 (en) | 2007-04-19 | 2014-11-25 | Mary Kay Inc | COMPOSITIONS CONTAINING MAGNOLIA EXTRACT |
| JP5523663B2 (en) * | 2007-11-05 | 2014-06-18 | 和夫 永井 | Pharmaceutical composition for promoting root-periodontal tissue formation |
| TWI422382B (en) | 2010-02-24 | 2014-01-11 | Colgate Palmolive Co | Enhancing the solubility of the magnolia active and the composition of the transport |
| TWI459957B (en) * | 2010-02-24 | 2014-11-11 | Colgate Palmolive Co | Oral care composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3314978B2 (en) * | 1993-04-19 | 2002-08-19 | 日本ゼトック株式会社 | Oral composition |
-
1996
- 1996-03-26 KR KR1019960008393A patent/KR0176015B1/en not_active Expired - Lifetime
-
1997
- 1997-03-26 AU AU21800/97A patent/AU2180097A/en not_active Abandoned
- 1997-03-26 WO PCT/KR1997/000048 patent/WO1997035599A1/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101704589B1 (en) * | 2016-07-12 | 2017-02-08 | 주식회사 뉴트라팜텍 | Composition comprising extracts of Magnolia flower and Magnolia officinlis for preventing or treating periodentitis as an active ingredient |
| WO2018012848A1 (en) * | 2016-07-12 | 2018-01-18 | 주식회사 뉴트라팜텍 | Pharmaceutical composition for stimulating periodontal tissue growth and preventing or treating periodontitis, containing mixture of magnoliae officinalis cortex extract and magnoliae flos extract as active component |
| KR102621090B1 (en) | 2023-08-20 | 2024-01-23 | 주식회사 구강닥터 | Drinking mouthwash composition capable of deodorizing and preventing tooth decay and its manufacturing method |
Also Published As
| Publication number | Publication date |
|---|---|
| KR970064617A (en) | 1997-10-13 |
| WO1997035599A1 (en) | 1997-10-02 |
| AU2180097A (en) | 1997-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0176015B1 (en) | Periodontal disease prevention and treatment composition | |
| JP3159509B2 (en) | Protease inhibitor | |
| KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
| KR101135172B1 (en) | A composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Phellodendron amurense Rupr, Houttuynia cordata, Paeonia lactiflora Pall, Agrimonia pilosa Ledeb, and Glycyrrhiza uralensis Fisch as an effective ingredient | |
| EP1444984B1 (en) | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes | |
| CN108464965A (en) | A kind of propolis mouthwash containing natural active ingredients and preparation method thereof | |
| RU2699560C1 (en) | Dental gel with a phytopeloid composition | |
| JPS61171423A (en) | Drug for alleviating dental caries and periodontosis | |
| JP2004067590A (en) | Female sex hormone production promoter and skin preparation for external use containing the same | |
| KR19980013946A (en) | Oral composition of liquid type | |
| KR100431170B1 (en) | Compositions for Dental Clinic Comprising Extracts of Plant | |
| KR100450391B1 (en) | Toothpaste Composition | |
| KR20020003413A (en) | Compositions of containing titrated extract of the unsaponifiable fraction of Zea Mays L. and extract of Magnoliae Cortex for prevention and treatment of periodontal disease | |
| CA2376367C (en) | Liquid composition for topical application | |
| JPH0253717A (en) | Dentifrice or mouth wash | |
| RU2334521C2 (en) | Coriander oil, compositions with anti-microbial and anti-inflammatory action containing coriander oil, and application thereof | |
| KR20190080504A (en) | Composition for the prevention and improvement of Periodontal Disease | |
| KR101703269B1 (en) | Oral care composition comprising Magnolia officinalis extract and bicarbonate | |
| KR100682979B1 (en) | Composition for prophylactic treatment against antimicrobial infection and anti-inflammatory action and athlete's foot therapeutic agent obtained using the composition | |
| KR102070316B1 (en) | Composition for treating or preventing oral diseases comprising natural complex | |
| KR0143191B1 (en) | Periodontal disease prevention and treatment composition | |
| JP2001172150A (en) | Composition for oral cavity and medicinal composition for external use | |
| CN115040582B (en) | Traditional Chinese medicine gingiva protection oral care product containing radix zanthoxyli extract | |
| RU2618889C1 (en) | Mouthwash agent having antiinflammatory, antimicrobial, wound-healing effect | |
| JPS6388117A (en) | Composition for oral cavity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19960326 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19960326 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19980826 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19981112 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19981112 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20010914 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20020830 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20031001 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20050217 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20051101 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20061031 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20071001 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20080617 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090910 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100331 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110425 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120328 Start annual number: 15 End annual number: 15 |
|
| FPAY | Annual fee payment |
Payment date: 20130327 Year of fee payment: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130327 Start annual number: 16 End annual number: 16 |
|
| FPAY | Annual fee payment |
Payment date: 20140306 Year of fee payment: 17 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140306 Start annual number: 17 End annual number: 17 |
|
| FPAY | Annual fee payment |
Payment date: 20150306 Year of fee payment: 18 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150306 Start annual number: 18 End annual number: 18 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |